MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Pancreatic and Hepatic Oncology Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,444 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,444 works in the cohort · of 4,299,418page 46 of 49

Labels cover 7 of 2,444 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,444 of 2,444 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
Shop Talk
2024· article· en· Oncology Times· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Challenging Topics in Pancreatic Neoplasia
Olca Baştürk, Alyssa M. Krasinskas
2020· article· en· Archives of Pathology & Laboratory Medicine· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study
Davide Melisi, Jens T. Siveke, Jean‐Frédéric Blanc, Daniel D. Von Hoff, Andrea Wang‐Gillam, L. Chen +4 more
2016· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
PANCREAS Tumors 106
Elijah Dixon, Charles M. Vollmer, Mark S. Cattral, David G. Grant, Bryce Taylor, B Langer +2 more
2003· article· en· Journal of Gastrointestinal Surgery· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Concurrent mutations in DNA damage repair genes <i>BRCA1</i> , <i>POLE</i> , <i>ATM</i> and <i>FANCA</i> to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.
Daniel J. Renouf, James T. Topham, Jonathan M. Loree, Dongsheng Tu, David F. Schaeffer, Jennifer J. Knox +14 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
← previousnext →

How this was built: Screen · Findings · About